Skip to main content
Signal8

BioStem Technologies, Inc. (BSEM)

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

BioStem Technologies, Inc. logo

BioStem Technologies, Inc.

NASDAQ:BSEMHealthcare
-13.18%$1.12
AH$1.19+6.25%vs close
Mkt Cap$21.19M
Float14.87M
O/S18.92M
Vol
$ Vol
RVOL
Inst Own0.0%
SI2.2%
Earnings
Dilution
FormDescription
424B3
EFFECT
Notice of Effectiveness
1
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
D
06b
S-8
REGISTRATION STATEMENT
5
S-1
8-K
EFFECT
Notice of Effectiveness
1
424B3
CORRESP
SEC Filing
1
UPLOAD
SEC Filing
D
06b
S-1
8-K
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
SEC STAFF LETTER
SEC Filing

1-25 of 73

Recent SEC filings with analysis